The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis

Zhou, Boyang; Dong, Jichen; Liang, Surong; Shang, Shuai; Li, Linfeng

doi:10.1080/17512433.2022.2120469

Cited by 8 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the blood count, we evaluated the patients' immune status by assaying total IgE, IgG, and IgA. Dupilumab, by inhibiting IL-4 and IL-13, both involved in IgE synthesis, indirectly leads to a reduction in IgE levels, as confirmed in our results and already shown in other studies [65]. IgG is the most abundant class of immunoglobulins in serum, accounting for more than 80% of total serum Ig.…”

Section: Discussionsupporting

confidence: 80%

Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Loperfido,

Ciofalo,

Cavaliere

et al. 2023

Journal of Immunology Research

View full text Add to dashboard Cite

Background. Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Objective. Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA. Method. A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome “La Sapienza” from December 2020 to January 2023. Results. A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges. Conclusion. To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.

show abstract

Section: Discussionsupporting

confidence: 80%

Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Loperfido,

Ciofalo,

Cavaliere

et al. 2023

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Participants received Dupilumab for 52 weeks, and the total IgE and specific IgE levels decreased more than 80% [29,30]. The study echoed results of previous trials [31]. These findings support future researches with Dupilumab as a possible therapy for food allergy.…”

Section: Therapies Targeting Interleukin-4 and Interleukin-13supporting

confidence: 84%

Biologicals in IgE-mediated food allergy

Mutarelli

Giavina-Bianchi

Arasi

et al. 2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewA better understanding of the most recent scientific literature in the use of biological therapy in the treatment of patients with IgE-mediated food allergy. Recent findingsA systematic review and meta-analysis demonstrated safety and effectiveness of omalizumab in the treatment of food allergy. The findings support the potential use of omalizumab as a monotherapy or as an adjunct to oral immunotherapy in IgE-mediated cow's milk allergy. The potential use of other biologics in the management of food allergy is subject of speculation. SummaryDifferent biological therapies are under evaluation for food allergic patients. The advance in literature will guide for a personalized treatment in the near future. However, additional research is needed to better understand the best candidate for each treatment, the optimal dose and timing.

show abstract

“…IgE levels of P1 decreased following dupilumab treatment. Reduced IgE levels were previously shown in dupilumab-treated patients, as demonstrated in a meta-analysis of seven studies ( 39 ). Published reports of DN- STAT3 patients treated with dupilumab with subsequent IgE reduction further support that notion ( 15 , 17 ).…”

Section: Discussionmentioning

confidence: 57%

Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience

et al. 2022

View full text Add to dashboard Cite

BackgroundAutosomal dominant hyper-IgE syndrome (AD-HIES) caused by dominant negative (DN) variants in the signal transducer and activator of transcription 3 gene (STAT3) is characterized by recurrent Staphylococcal abscesses, severe eczema, chronic mucocutaneous candidiasis (CMC), and non-immunological facial and skeletal features.ObjectivesTo describe our experience with the diagnosis and treatment of adult patients with AD-HIES induced by DN-STAT3 variants.MethodsThe medical records of adult patients (>18 years) treated at the Allergy and Clinical Immunology Clinic of Hadassah Medical Center, Jerusalem, Israel, were retrospectively analyzed. Immune and genetic workups were used to confirm diagnosis.ResultsThree adult patients (2 males; age 29-41 years) were diagnosed with DN-STAT3 variants. All patients had non-immunological features, including coarse faces and osteopenia. Serious bacterial infections were noted in all patients, including recurrent abscesses, recurrent pneumonia, and bronchiectasis. CMC and diffuse dermatophytosis were noted in two patients. Two patients had severe atopic dermatitis refractory to topical steroids and phototherapy. Immune workup revealed elevated IgE in three patients and eosinophilia in two patients. Whole exome sequencing revealed DN-STAT3 variants (c.1166C>T; p.Thr389Ile in two patients and c.1268G>A; p. Arg423Gln in one patient). Variants were located in DNA-binding domain (DBD) and did not hamper STAT3 phosphorylation Treatment included antimicrobial prophylaxis with trimethoprim/sulfamethoxazole (n=2) and amoxycillin-clavulanic acid (n=1), and anti-fungal treatment with fluconazole (n=2) and voriconazole (n=1). Two patients who had severe atopic dermatitis, were treated with dupilumab with complete resolution of their rash. No adverse responses were noted in the dupilumab-treated patients.DiscussionDupilumab can be used safely as a biotherapy for atopic dermatitis in these patients as it can effectively alleviate eczema-related symptoms. Immunologists and dermatologists treating AD-HIES adult patients should be aware of demodicosis as a possible manifestation. DN-STAT3 variants in DBD do not hamper STAT3 phosphorylation.

show abstract

The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis

Cited by 8 publications

References 33 publications

Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Biologicals in IgE-mediated food allergy

Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience

Contact Info

Product

Resources

About